D-PATH AI IHC QUANTIFICATION

AI IHC Quantification in breast cancer, lung cancer, and beyond AI quantitative analysis is utilized for the assessment of biomarkers such as KI67, ER, PR, HER-2, PD-L1, and CD30. It offers objective and accurate quantitative data, which supports molecular subtyping of cancer and contributes to research and development in targeted therapies.

HER-2 IHC QUANTIFICATION ASSISTANCE PLATFORM

About it

According to ASCO guidelines, the system analyzes the HER-2 WSI of breast cancer, excluding ductal carcinoma in situ. It quantifies and categorizes tumor cells based on membrane integrity and varying levels of positive expression, calculating the number and percentage of each type of positive tumor cell. This provides an objective diagnostic basis for HER2-ultralow classification.

Validation was conducted using routine IHC HER-2 diagnostic slides from leading hospitals in China, compared with pathologists, the overall AI results are as follows:

Effective tools

>

Real-time
consultation

>

Customized
model

>

Dual-screen
comparison

>

Dynamic
Tracking

  1. Li M et al. Artificial Intelligence Assisted Assessment of HER2-ultralow and HER2-low Immunohistochemical Scoring in Breast Cancer Core Needle Biopsy Specimens. 2024 USCAP: Abstract #178.

  2. Li, H. et al. (2023). Segment Membranes and Nuclei from Histopathological Images via Nuclei Point-Level Supervision. In: Greenspan, H., et al. Medical Image Computing and Computer Assisted Intervention – MICCAI 2023. MICCAI 2023. Lecture Notes in Computer Science, vol 14225. Springer, Cham. https://doi.org/10.1007/978-3-031-43987-2_52

  3. Ming Li, Hong Lv, Yizhi Zhao, Chenglu Zhu, Hansheng Li, Mingzhen Lin, Wen-Tao Yang; Abstract PO4-26-09: The Advantage of Artificial-Intelligence in HER2 IHC 0 and 1+ Scoring in Breast Cancer. Cancer Res 1 May 2024; 84 (9_Supplement): PO4–26–09. https://doi.org/10.1158/1538-7445.SABCS23-PO4-26-09

  4. Li H, Kang Y, Yang W, Wu Z, Shi X, Liu F, Liu J, Hu L, Ma Q, Cui L, Feng J, Yang L. A Robust Training Method for Pathological Cellular Detector via Spatial Loss Calibration. Front Med (Lausanne). 2021 Dec 14;8:767625. doi: 10.3389/fmed.2021.767625. PMID: 34970560; PMCID: PMC8712578.

Ready to contact

  • * Last Name
  • First Name
  • Organization
  • Country/Region
  • E-mail
  • Phone Number
  • Areas of Interest
  • Message
  • Captcha

Phone: +86 400-891-0357

Address: Room 1204, Building 3, No. 801 Huiping Road, ​Jiading District, Shanghai, China